April 25th 2025
After delays in the review of the COVID-19 vaccine—which missed its April 1 review deadline—the agency has requested new data.
April 23rd 2025
The University of California San Francisco and Gladstone Institutes develop compounds with a 1,000,000-fold reduction in viral titers and 1000 times effective concentration in the brain.
April 21st 2025
Study of 400,000 pediatric records shows vaccine’s effectiveness in preventing Long COVID during Delta and Omicron waves.
April 17th 2025
A large study showed these SARS-CoV-2 positive groups were more prone to myocarditis, heart failure, arrhythmias, and chest pain—regardless of prior cardiovascular history or presence of congenital heart disease (CHD).
April 10th 2025
A new phase 2 trial raises questions about nirmatrelvir-ritonavir’s broader efficacy, as other studies highlight its effectiveness in reducing mortality among immunocompromised COVID-19 patients.
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Critical Voices: Black and Latinx Community Perspectives on COVID-19
July 26th 2021Communities experiencing such health inequity and disparities are more likely to have mistrust in systems that have continuously failed them. Understanding the perspectives of those disproportionately affected is critical to not only address them, but also work to correct and prevent these disparities moving forward.
Read More
Lambda Variant Concerns: Transmissibility, Vaccine Efficacy
July 23rd 2021The lineage C.37, (Lambda variant), was recently classified as a variant of interest by the World Health Organization (WHO) based on its high circulation rates in South America, and has showed "the ability to escape from neutralizing antibodies elicited by CoronaVac."
Read More
2 Commerce Drive
Cranbury, NJ 08512